Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Recruiting	DEU	0
NCT00770263	Phase I	Erlotinib + Temsirolimus	Erlotinib and Temsirolimus for Solid Tumors	Completed	USA	0
NCT02925234	Phase II	Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT03673787	Phase Ib/II	Atezolizumab + Ipatasertib	A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP)	Unknown status	GBR	0
NCT05691465	Phase II	lutetium Lu 177 dotatate	Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells	Recruiting	USA	0
NCT04251533	Phase III	Alpelisib + Nab-paclitaxel Nab-paclitaxel	Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| AUT \| AUS	22
NCT01458067	Phase I	GSK2636771	A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency	Completed	USA \| GBR	1
NCT04586270	Phase I	TAS0612	A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer	Recruiting	USA \| FRA	0
NCT06218667	Phase Ib/II	Copanlisib + Degarelix	A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer	Recruiting	USA	0
NCT05810870	Phase II	Eribulin + MEN1611 MEN1611	PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (SABINA)	Recruiting	ESP	0
NCT03065062	Phase I	Gedatolisib + Palbociclib	Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors	Recruiting	USA	0
NCT03317119	Phase I	Trametinib + Trifluridine-tipiracil hydrochloride	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	Completed	USA	0
NCT01884285	Phase I	AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib	AZD8186 First Time In Patient Ascending Dose Study	Completed	USA \| GBR \| ESP \| CAN	0
NCT01870726	Phase Ib/II	Buparlisib + Capmatinib	Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma	Terminated	USA \| NLD \| ESP \| DEU	1
NCT04592237	Phase II	Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	Recruiting	USA	0
NCT02987959	Phase II	Sapanisertib	Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas	Terminated	USA	0
NCT04737109	Phase Ib/II	Darolutamide + Ipatasertib	Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer	Terminated	USA	0
NCT02920450	Phase Ib/II	Carboplatin + Gedatolisib + Paclitaxel	Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)	Terminated	USA	0
NCT05773326	Phase I	Temsirolimus	Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG	Recruiting	USA	0
NCT02576444	Phase II	Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib	OLAParib COmbinations (OLAPCO)	Terminated	USA	0
NCT03624543	Phase II	CFI-400945	CFI-400945 in Patients With Advanced/Metastatic Breast Cancer	Active, not recruiting	CAN	0
NCT02549989	Phase II	LY3023414	Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer	Completed	USA	0
NCT02215096	Phase I	Enzalutamide GSK2636771	Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer	Completed	USA \| GBR	0
NCT02761694	Phase I	ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant	ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations	Terminated	USA	0
NCT04388852	Phase I	DS-3201b + Ipilimumab	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	Recruiting	USA	0
NCT03131908	Phase Ib/II	GSK2636771 + Pembrolizumab	Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss	Active, not recruiting	USA	0
NCT04632992	Phase II	Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib	A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)	Completed	USA	0
NCT02961283	Phase I	ASN003	Study of ASN003 in Subjects With Advanced Solid Tumors	Terminated	USA	0
NCT03834740	Phase I	Everolimus + Ribociclib	A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection	Completed	USA	0
NCT05300048	Phase I	Serabelisib Nab-paclitaxel + Serabelisib	Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations	Active, not recruiting	USA	0
NCT05082025	Phase II	Copanlisib + Fulvestrant	Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations	Active, not recruiting	USA	0
NCT06029998	Phase II	Bortezomib	Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion (BORXPTEN)	Recruiting	USA	0
NCT05038839	Phase I	Cabozantinib + Pamiparib	Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors	Recruiting	USA	0
NCT05843253	Phase II	Everolimus + Ribociclib	Study of Ribociclib and Everolimus in HGG and DIPG	Not yet recruiting	USA \| NLD \| GBR \| DEU \| CAN \| AUS	0
NCT03207529	Phase I	Alpelisib + Enzalutamide	Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer	Completed	USA	0
NCT03088059	Phase II	Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil	Biomarker-based Study in R/M SCCHN (UPSTREAM)	Active, not recruiting	ITA \| GBR \| FRA \| ESP \| BEL	0
NCT03360721	Phase II	Abiraterone + Apalutamide + Prednisone	Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer	Active, not recruiting	USA	0
NCT03218826	Phase I	AZD8186 + Docetaxel	PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT04317105	Phase Ib/II	Copanlisib + Ipilimumab + Nivolumab Copanlisib + Nivolumab	Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN	Active, not recruiting	USA \| CAN	0
NCT04216472	Phase II	Alpelisib + Nab-paclitaxel	Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations	Active, not recruiting	USA	0
NCT03842228	Phase I	Copanlisib + Durvalumab + Olaparib	Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations	Active, not recruiting	USA	0
NCT02401347	Phase II	Talazoparib	Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors	Completed	USA	0
NCT05010096	Phase I	Copanlisib + Elimusertib	BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	Withdrawn		0
NCT03209401	Phase I	Carboplatin + Niraparib	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies	Terminated	USA	0
NCT05379972	Phase II	Olaparib + Pembrolizumab	Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers	Recruiting	USA	0
NCT06239467	Phase I	OKI-219 + Trastuzumab OKI-219 Fulvestrant + OKI-219	First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01)	Recruiting	USA	0
NCT02189174	Phase Ib/II	CLR457	Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies	Terminated	USA \| ESP \| CAN	2
NCT04770246	Phase II	TAS-117	TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations	Terminated	USA \| GBR \| FRA \| AUT	0
NCT04108858	Phase Ib/II	Copanlisib + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab	Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer	Terminated	USA	0
NCT01097278	Phase 0	Cholecalciferol	S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer	Completed	USA	0
NCT04493853	Phase III	Abiraterone + Capivasertib Abiraterone	Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)	Active, not recruiting	USA \| NLD \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	22
NCT02644122	Phase II	SF1126	SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes	Terminated	USA	0
NCT03337724	Phase II	Ipatasertib + Paclitaxel Paclitaxel	A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)	Completed	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	21
NCT01306045	Phase II	Erlotinib Lapatinib MK2206 Sunitinib Selumetinib	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies	Active, not recruiting	USA	0
NCT01971515	Phase I	M2698	First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies	Completed	USA	0
NCT01470209	Phase I	Buparlisib + Everolimus	A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies	Completed	USA	0
NCT01396408	Phase II	Temsirolimus Sunitinib	A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours	Active, not recruiting	CAN	0
NCT04774952	Phase I	RMC-5552	Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors	Active, not recruiting	USA	0
NCT05768139	Phase Ib/II	Fulvestrant + STX-478 STX-478	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors	Recruiting	USA \| ESP	0
NCT04958226	Phase I	Capivasertib + Midazolam	A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours	Completed	USA	0
NCT02315625	Phase II	Everolimus Sunitinib	Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery	Terminated	USA	0
NCT03207347	Phase II	Niraparib	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	Completed	USA	0
NCT02523014	Phase II	Abemaciclib GSK2256098 Vismodegib Capivasertib	Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	Recruiting	USA	0
NCT03297606	Phase II	Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)	Recruiting	CAN	0
NCT04042831	Phase II	Olaparib	Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations	Recruiting	USA	0
NCT05933395	Phase II	Abemaciclib + Fulvestrant Fulvestrant + Neratinib Alpelisib + Fulvestrant Everolimus + Fulvestrant	Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (GERTRUDE)	Recruiting	USA	0
NCT01226316	Phase I	Capivasertib	Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| CAN	3

Gene Detail

Contact

Filtering

Sorting